Search results for

IP protection in China remains a controversial and politicised issue. Mark Cohen looks back at his four years working as IP attaché at the US Embassy in Beijing

Liu Shen & Associates, Beijing

Governments should consider setting up bodies to reduce the barriers for SMEs entering the patenting process and improve the quality of applications, argues Rafaël Kiebooms

In a recent decision, the German Federal Court of Justice (BGH) ruled that a patent claiming a technical effect that is not indicated in the priority application may still validly claim priority if the obtaining of the effect seems self-evident to a person skilled in the art when reworking the disclosed invention (BGH X ZR 107/04).

Malaysia acceded to the Patent Cooperation Treaty (PCT) on August 16 2006. Thereafter, all PCT patent applications filed on or after that date automatically designated Malaysia. In order to enter the national phase in Malaysia, the time limits under PCT Chapters I and II are before the expiration of 30 months from the priority date under Section 780 of Malaysian Patents Act 1983. However, some of these PCT applications have often missed the 30 months deadline to file a request to enter national phase in Malaysia due to the applicant's failure to file the said request on time.

Taiwan's Intellectual Property Office is to amend the compulsory licensing provisions of its Patent Law after a long-running dispute between a local CD maker and Philips finally ended

An OAPI registered right extends automatically to all member states at the date of registration. The 1977 Bangui Agreement contained no provision for extending rights to states that acceded afterwards but Article 19(a) empowered the Administrative Council to make Regulations "necessary for the application" of the Agreement. That power was perpetuated in the 1999 version of Bangui.

I'm an in-house trade mark counsel for a famous brand and we are thinking about applying for a new gTLD. What issues do we need to consider and should we make an application?

Boehringer Ingelheim Pharmaceuticals filed a patent application titled "Pharmaceutical composition". The invention relates to a paediatric suspension of nevirapine hemihydrate. The application was filed with a total of six claims and upon its examination, the examiner raised objections on the grounds of non-patentability and definitiveness of the claims. The applicant, in compliance with the objections, then amended the claims.

As more and more US courts become patent-savvy, it is important to understand the procedural differences between the main venues. Authors in five districts and the ITC answer your questions